vs

Side-by-side financial comparison of FRIEDMAN INDUSTRIES INC (FRD) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $168.0M, roughly 1.9× FRIEDMAN INDUSTRIES INC). FRIEDMAN INDUSTRIES INC runs the higher net margin — 1.8% vs -18.2%, a 20.1% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 78.6%). FRIEDMAN INDUSTRIES INC produced more free cash flow last quarter ($-6.3M vs $-133.8M).

Hellman & Friedman (H&F) is an American private equity firm founded in 1984 by Warren Hellman and Tully Friedman that makes investments primarily through leveraged buyouts as well as growth capital investments. It has focused its efforts on several core target industries including media, financial services, professional services and information services.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

FRD vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.9× larger
MDGL
$321.1M
$168.0M
FRD
Growing faster (revenue YoY)
MDGL
MDGL
+132.2% gap
MDGL
210.8%
78.6%
FRD
Higher net margin
FRD
FRD
20.1% more per $
FRD
1.8%
-18.2%
MDGL
More free cash flow
FRD
FRD
$127.5M more FCF
FRD
$-6.3M
$-133.8M
MDGL

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
FRD
FRD
MDGL
MDGL
Revenue
$168.0M
$321.1M
Net Profit
$3.0M
$-58.6M
Gross Margin
2.3%
Operating Margin
2.3%
-18.6%
Net Margin
1.8%
-18.2%
Revenue YoY
78.6%
210.8%
Net Profit YoY
364.1%
1.4%
EPS (diluted)
$0.43
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRD
FRD
MDGL
MDGL
Q4 25
$168.0M
$321.1M
Q3 25
$152.4M
$287.3M
Q2 25
$134.8M
$212.8M
Q1 25
$137.3M
Q4 24
$94.1M
$103.3M
Q3 24
$106.8M
$62.2M
Q2 24
$114.6M
Q1 24
$0
Net Profit
FRD
FRD
MDGL
MDGL
Q4 25
$3.0M
$-58.6M
Q3 25
$2.2M
$-114.2M
Q2 25
$5.0M
$-42.3M
Q1 25
$-73.2M
Q4 24
$-1.2M
$-59.4M
Q3 24
$-675.0K
$-107.0M
Q2 24
$2.6M
Q1 24
$-147.5M
Gross Margin
FRD
FRD
MDGL
MDGL
Q4 25
2.3%
Q3 25
1.9%
Q2 25
5.2%
Q1 25
96.7%
Q4 24
Q3 24
-0.2%
Q2 24
-1.2%
Q1 24
Operating Margin
FRD
FRD
MDGL
MDGL
Q4 25
2.3%
-18.6%
Q3 25
1.9%
-39.7%
Q2 25
5.2%
-22.2%
Q1 25
-57.8%
Q4 24
-1.3%
-64.8%
Q3 24
-0.2%
-187.1%
Q2 24
-1.2%
Q1 24
Net Margin
FRD
FRD
MDGL
MDGL
Q4 25
1.8%
-18.2%
Q3 25
1.5%
-39.8%
Q2 25
3.7%
-19.9%
Q1 25
-53.4%
Q4 24
-1.2%
-57.5%
Q3 24
-0.6%
-172.0%
Q2 24
2.2%
Q1 24
EPS (diluted)
FRD
FRD
MDGL
MDGL
Q4 25
$0.43
$-2.55
Q3 25
$0.32
$-5.08
Q2 25
$0.71
$-1.90
Q1 25
$-3.32
Q4 24
$-0.17
$-2.50
Q3 24
$-0.10
$-4.92
Q2 24
$0.37
Q1 24
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRD
FRD
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$3.0M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$142.2M
$602.7M
Total Assets
$311.9M
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRD
FRD
MDGL
MDGL
Q4 25
$3.0M
$198.7M
Q3 25
$4.6M
$295.7M
Q2 25
$2.1M
$186.2M
Q1 25
$183.6M
Q4 24
$1.1M
$100.0M
Q3 24
$2.5M
$232.7M
Q2 24
$4.1M
Q1 24
$622.5M
Total Debt
FRD
FRD
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
FRD
FRD
MDGL
MDGL
Q4 25
$142.2M
$602.7M
Q3 25
$139.3M
$625.7M
Q2 25
$137.3M
$696.0M
Q1 25
$710.6M
Q4 24
$127.3M
$754.4M
Q3 24
$128.8M
$777.2M
Q2 24
$129.7M
Q1 24
$850.8M
Total Assets
FRD
FRD
MDGL
MDGL
Q4 25
$311.9M
$1.3B
Q3 25
$311.3M
$1.4B
Q2 25
$219.1M
$1.0B
Q1 25
$996.6M
Q4 24
$210.3M
$1.0B
Q3 24
$209.2M
$1.1B
Q2 24
$222.8M
Q1 24
$1.1B
Debt / Equity
FRD
FRD
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRD
FRD
MDGL
MDGL
Operating Cash FlowLast quarter
$-4.7M
$-133.5M
Free Cash FlowOCF − Capex
$-6.3M
$-133.8M
FCF MarginFCF / Revenue
-3.8%
-41.7%
Capex IntensityCapex / Revenue
1.0%
0.1%
Cash ConversionOCF / Net Profit
-1.56×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRD
FRD
MDGL
MDGL
Q4 25
$-4.7M
$-133.5M
Q3 25
$434.0K
$79.8M
Q2 25
$15.5M
$-47.1M
Q1 25
$-88.9M
Q4 24
$-104.5M
Q3 24
$-67.0M
Q2 24
$-6.1M
Q1 24
$-149.2M
Free Cash Flow
FRD
FRD
MDGL
MDGL
Q4 25
$-6.3M
$-133.8M
Q3 25
$-2.0M
$79.0M
Q2 25
$13.7M
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
$-7.1M
Q1 24
$-149.5M
FCF Margin
FRD
FRD
MDGL
MDGL
Q4 25
-3.8%
-41.7%
Q3 25
-1.3%
27.5%
Q2 25
10.2%
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
-6.2%
Q1 24
Capex Intensity
FRD
FRD
MDGL
MDGL
Q4 25
1.0%
0.1%
Q3 25
1.6%
0.3%
Q2 25
1.3%
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
0.9%
Q1 24
Cash Conversion
FRD
FRD
MDGL
MDGL
Q4 25
-1.56×
Q3 25
0.19×
Q2 25
3.08×
Q1 25
Q4 24
Q3 24
Q2 24
-2.36×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRD
FRD

Prime Coil$152.0M90%
Manufactured Pipe$14.9M9%
Customer Owned$1.1M1%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons